article thumbnail

Novartis offers $17.7m support in the fight for health equity

Outsourcing Pharma

The pharmaceutical company is expanding its alliance with historically Black medical schools to bolster the battle against systemic health disparities.

article thumbnail

STAT+: Q&A: Califf on obesity drugs, advisory panels, and how threats hurt recruitment at FDA

STAT

BOSTON — FDA Commissioner Robert Califf said on Monday that it “bothers” him that Novo Nordisk, which makes an obesity medication, funded the development of obesity coursework for medical schools.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: Walgreens won’t dispense abortion pills in several states; Lilly avoids paying Medicaid rebates with insulin price cuts

STAT

… A two-part message is permeating the halls of medicine and the fabric of society, sliding into medical school lectures, pediatrician offices, happy hours, and social feeds: Obesity is a chronic biological disease — and it is treatable with a new class of medications , STAT explains.  The

article thumbnail

TPD Assay Development & Screening Summit

pharmaphorum

Expert speaking companies include Plexium , Stanford University Medical School, Seed Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson, Kymera Therapeutics, Foghorn Therapeutics & many more. View the full event guide here.

article thumbnail

7. Reflections on a Career in Pharmacy and Medicine with Dr. Steven Berk

The Physician Pharmacist

The MCAT: Everything You Need To Know How Hard is Medical School Can you work while in Medical School? The Physician Pharmacist Do's and Don'ts 6 Most Common Questions About Transitioning From Pharmacy to Medicine The Art of Applying to Medical School (The Pharmacy Student Edition)!

article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

Pharmaceutical companies and biotechs are also adapting their approaches, launching patient finding and engagement programmes that can start years before clinical trials begin and allow them to run ‘recontact by genotype’ studies that the Resilience Project would have liked to do.

article thumbnail

Pharmacovigilance deep dive: risk minimisation measures

European Pharmaceutical Review

She has worked with regulatory agencies and pharmaceutical companies for over 10 years. She also has been conducting fundamental research as an academic in several universities, with her last academic position held at Harvard Medical School. Before that she has been an independent scientific advisor. About the author.